F 16915

F 16915 is a docosahexaenoic acid derivative which can prevent heart failure-induced atrial fibrillation.

Signaling Pathways >> Others >> Others

Research Areas >> Cardiovascular Disease

F 16915 is a docosahexaenoic acid derivative which can prevent heart failure-induced atrial fibrillation. Time-dependent changes in blood concentrations of total docosahexaenoic acid (DHA) and nicotinyl alcohol are followed after a single oral administration of F 16915 (300 mg/kg) to male rats. Treatment with F 16915 has no significant effect on body weight: 27.7±2.9 kg and 28.1±1.0 kg before surgery versus 29.2±3.4 kg and 28.8±1.7 kg after in the 1 and 5 g/day groups, respectively. F 16915 administered at 5 g/day for 4 weeks significantly reduces the mean duration of Atrial fibrillation (AF) induced by burst pacing but has no significant effect at 1 g/day. The duration of AF is significantly reduced from 989±111 s in the placebo group to 79±59 s in the presence of F 16915 at 5 g/day. Treatment of 2 months with 100 mg/kg F 16915 also significantly reduces the infarct size[1].

Male Sprague-Dawley rats weighing 220 to 300 g are used in this study. The rats are anesthetized using isoflurane 3% on O2. Then, the animals are intubated and ventilated at 60 respirations/min (2.5 mL/respiration) while anesthesia is maintained. A left thoracotomy is performed, and a silk suture is placed around the left coronary artery ~1 mm from its origin. The treatment starts just after the surgery. A single administration of 100 mg/kg F 16915 or vehicle (olive oil) is daily administrated orally by force-feeding[1].

[1]. Le Grand B, et al. F 16915 prevents heart failure-induced atrial fibrillation: a promising new drug as upstream therapy. Naunyn Schmiedebergs Arch Pharmacol. 2014 Jul;387(7):667-77.

Captisol | Cyclosporin A | H2DCFDA | 0MPTP hydrochloride | GW4869 | Etomoxir | TD139 | Mitoquinone mesylate | GSK2795039 | JC-1 | BAPTA-AM | AP 20187 | Setanaxib (GKT137831) | D-Luciferin | Crotaline